

Stay confident in your biomarker scoring – every time

Manual biomarker scoring can be both time-consuming and inconsistent — challenges that become even more critical with classifications like HER2-low and -ultralow. The Insight platform enables AI-driven, fully automated image analysis APPs to provide precise, reliable biomarker scoring. With Insight, you can eliminate variability and focus on what truly matters: making confident, informed decisions.

The Insight Advantages


- **Improved consistency** – Standardized quantification ensures reproducibility across samples and pathologists.
- **Faster results** – AI-powered, high-throughput automation streamlines workflows and reduces turnaround time.
- **Focus on decisions, not manual work** – Minimize time spent on manual assessment and more on making informed decisions.
- **Confidence in every call** – Accurate biomarker assessments aligned with guidelines for clear, precise results.
- **Seamless integration** – Works with major PACS/IMS/LIS systems, including Proscia, Sectra, PathAI, Fujifilm, INFINITT, Corista, Paige, Philips, and more.



Insight results displayed in the Sectra IDS7.




Our fully automated, AI-based image analysis provides precise quantifications to assess biomarker expressions for evaluation in various cancer indications.




HER2, breast cancer

Fully automated single-cell approach for HER2 Score assessment, bringing confidence to scoring also low expression cases.




Ki-67, breast cancer

Quantifies cell proliferation in invasive tissue, returning a proliferation index for the entire tumor region.




ER & PR, breast cancer

These two APPs measure ER and PR positivity and provide the percentage of positive cells, the total cell number as well as an Allred score.




PD-L1, lung cancer (NSCLC)

Evaluates whole tumor sections and returns a Tumor Proportion Score (TPS), ensuring objective PD-L1 expression analysis.




Lymph node metastasis, breast & colon cancer

Identifies even small and hard-to-spot metastases in lymph nodes (H&E), enhancing sensitivity and reducing the need for additional IHC staining.




Prostate cancer, detection and grading, H&E (IVDD)

Detects invasive tumor areas in needle core biopsies and provides automated Gleason scoring, ensuring objective and reproducible grading.



CE 2797 CE IVD – for use in diagnostic procedures.
Not for sale outside the EU/UK.

Ready to bring confidence and reproducibility to your biomarker assessment?



Contact us

16978-05-2025